April 14, 2020 – KGK Science has been recognized by the Global Health & Pharma (GHP) Medical Marijuana Awards as the Best Nutraceutical and Cannabinoid Full-Service CRO 2020. GHP hosts the Medical Marijuana Awards annually to recognize organizations that have facilitated the rise and success of cannabinoid products in the global market. This win speaks to KGK’s position as thought-leaders in cannabinoid science and regulation for the natural health product industry.
“We are dedicated to being on the cutting-edge of cannabis research, expanding on our expertise in the nutraceutical industry,” says Najla Guthrie, President & CEO at KGK Science. “This recognition by GHP is a welcomed acknowledgment of our passion for moving the cannabis industry forward with innovative research and regulatory expertise to support our clients in bringing safe and effective products to market.”
KGK stands out amongst its competitors as the first CRO in Canada to apply for a Cannabis Research License from Health Canada, leading the charge in firsts and innovation in the cannabinoid research space. Two cannabis clinical trials are currently being conducted at their London, Ontario facility, both of which would bring value to the global body of cannabis research.
KGK Science Partners with Zentrela to Test Ontario Government-Funded Cannabis Impairment Device
KGK Science Secures Cannabis Research License for a Clinical Trial Sponsored by New Age Nanotech
As a trusted partner for companies looking to bring new cannabis products to market, KGK Science would like to thank GHP for this award, subsequently furthering its mission to provide the highest quality of service while driving health and wellness innovation forward within the cannabis industry.
Contact: Lauren Redman, Director of Marketing | (519) 438-9374 x 254 | firstname.lastname@example.org